EMERGING TECHNOLOGY PARTNERS

Wei-Wu He, PhD

General Partner

Wei-Wu is a General Partner and Co-founder of Emerging Technology Partners LLC. Prior to ETP, he was the founder and president of OriGene Technologies, Inc. Dr. He was also one of the first few employees of Human Genome Sciences, Inc. (NSDQ: HGSI). Dr. He has been involved in over 20 biotech companies through his career.

Dr. He has been awarded over 20 U.S. patents and has more than twenty original research publications. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and conducted cancer research at Mayo Clinic and at Massachusetts General Hospital. He received his MBA from the Wharton School.

Bill Snider, CFA

Founding Partner

Bill Snider, CFA is a general partner and co-founder of Emerging Technology Partners, LLC. Prior to ETP he was a mutual fund portfolio manager at T. Rowe Price. Mr. Snider joined T. Rowe Price in 1991 after attending the Wharton School. Shortly thereafter he became the youngest vice president and portfolio manager in the firm’s 60-year history. His responsibilities included managing $2 billion of mutual fund and institutional client portfolios.

Mr. Snider’s current and past directorships include Alpha Innotech, Atto Biosciences and Marligen Biosciences.

He holds the Chartered Financial Analysts accreditation and an MBA from the Wharton School.

OUTSIDE ADVISORS

Frank A. Bonsal, Jr.

Frank Bonsal is a well-known and highly regarded venture capitalist with significant experience in helping start-up companies become successful. Mr. Bonsal is co-founder of New Enterprise Associates (NEA), one of the largest venture capital firms in the United States. Since founding NEA in 1978, he has focused on the development of its early stage companies.

Frank's current board memberships include Advertising.com, Inc., Baltimore, Maryland; AmCare Labs International, Lutherville, Maryland; COVEGA Corporation, Jessup, Maryland, CeraTech, Baltimore, Maryland and Cibernet Corporation, Bethesda, Maryland. In addition, he is a special limited partner of Amadeus Capital Partners, Boulder Ventures, Novak Biddle, Trellis Ventures, and Windward Ventures. His community commitments include membership on the Johns Hopkins Hospital Endowment Board. Previously, he was a director of Aspect Medical Systems, Inc.; Biopure Corporation; Corvis Corporation Aether Systems Inc; Entevo Corporation; GeneScreen, Inc.; Synaptic Pharmaceuticals; Torrent Network Technology; and Vertex Pharmaceuticals. Mr. Bonsal has played a significant role in helping these companies with business development issues.

NEA, with $6 billion under management, is the leading start-up venture capital firm in the country. For more than 25 years, NEA has practiced classic venture capital by investing in early stage companies and working with management to nurture and build companies of lasting value. NEA has invested in more than 400 companies, of which more than 130 have gone public and more than 150 have been successfully acquired.

Prior to NEA, Mr. Bonsal was a general partner of Alex. Brown & Sons (1968 - 1977). He received a Bachelor of Arts in American Studies and Economics from Princeton University (1959).

Nancy Chang

As Chief Executive Officer of Tanox, Inc., Dr. Chang draws on 22 years of biotechnology experience to guide the Company's strategic vision and oversee operations. Dr. Chang also served as the president and chairman of the board of directors since she co-founded the Company in 1986 to address significant unmet medical needs in the areas of asthma, allergy, inflammation, and diseases affecting the human immune system.

Before starting Tanox, Dr. Chang served as an associate professor at Baylor College of Medicine in the division of molecular virology and as director of research, molecular biology group, for Centocor, Inc., a biopharmaceutical company.

Dr. Chang has received numerous academic, national and international awards for her business acumen and contributions to the biopharmaceutical industry. She was inducted into the Texas Science Hall of Fame in 2001 for exemplary achievement in science and is the recipient of coveted awards such as the Associate of Women in Computing: Top 20 Houston Women in Technology, Who's Who National Registry and Houston Entrepreneur of the Year (sponsored by Ernst & Young, Inc. Magazine and Merrill Lynch). As an active member in the biopharmaceutical industry, she has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents.

Dr. Chang currently serves on the board of the Houston Technology Council and the Center for Houston's Future. She also has held leadership positions with various biotechnology, business and technology organizations including CSIS Council on Biotechnology Research, Innovation and Public Policy, the Governor's Advisory Committee on Biopharmaceuticals and the Texas Science and Technology Council.

Dr. Chang received her doctorate in biological chemistry from Harvard University.

Steven Frank

Senior Managing Director, Head of Worldwide Health Care Group---Mr. Frank is the Head of Bear Stearns' Worldwide Health Care Investment Banking Group. He joined the firm in 1993 focusing on providing general investment banking services to pharmaceutical, device, and biotechnology companies.

Mr. Frank has led or played major roles in the investment banking teams in dozens of merger and acquisitions and financing transactions across the spectrum of deal structures. In addition, he serves on the Investment Committee for Bear Stearns Health InnoVentures, a multi-million dollar life sciences venture fund managed by the firm's Merchant Banking division.

Prior to joining Bear Stearns in 1993, Mr. Frank served over ten years as an institutional investor, primarily at State Farm Insurance Company, where he managed a life sciences portfolio in excess of $4 billion. Mr. Frank earned an M.B.A. from the University of Chicago in 1983.

Joel Marcus

Joel S. Marcus has been Chief Executive Officer of Alexandria Real Estate since March 1997 and has served as a director since the Company's inception. Mr. Marcus was previously Vice Chairman and Chief Operating Officer from inception to his appointment as Chief Executive Officer. He was Secretary from inception to April 1997. From 1986 to 1994,

Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison, LLP (including a predecessor firm), specializing in corporate finance and capital markets, venture capital and mergers and acquisitions, in the bio-pharmaceutical industry. From 1984 to 1994, he also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture which financed the development of, and owned patents to, two multi-billion dollar genetically-engineered biopharmaceutical products.

Mr. Marcus was formerly a practicing certified public accountant specializing in the financing and taxation of real estate. He received his undergraduate and Juris Doctor degrees from the University of California at Los Angeles. He is a member of the National Association of Real Estate Investment Trusts (NAREIT). Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles--Real Estate).

BACK TO THE TOP